Abstract: Objective To evaluate the disease progression and posttreatment survival of autologus dendritic cells （ADC） vaccine on patients with estrogen receptor／progestin receptor doublenegative stage Ⅱ／ⅢA breast cancer. MethodsADC vaccines were generated from CD14+precursors pulsed with autologous tumor lysates. ADCs were matured with defined factors. Sixty-three patients were divided into the experimental group and control group. The experimental group was immunized intradermally four times. The levels of IFN-γ+／CD8+T cells in experimental group before and after vaccination were detected. Type Ⅳ allergic reaction against the tumor lysate of both groups was measured. Disease progression rates were analyzed. ResultsThe level of IFN-γ+／CD8+T cells increased after vaccination，higher than that before vaccination（23.4±4.1％ vs. 14.3±2.0％，P＜0.05）.Eighteen patients in experimental group had positive type Ⅳ allergic reactions， while all patients in control group were negative （P＜0.05）. The 3-year progression free rate of experimental group was higher than that of control group （76.9％ vs. 31.0％， P＜0.05）. There were no unanticipated or serious adverse effects. Conclusion ADC vaccine might treat breast cancer by triggering immune responses of patients.